Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Both hormones act as agonists at their respective receptors on ovarian cells. Follicle‑Stimulating Hormone promotes growth and maturation of ovarian follicles, while Luteinising Hormone triggers the final maturation and ovulation of the dominant follicle. Together they restore the natural hormonal cascade required for successful ovulation and conception.

The dose of Meriofert is individualized by the prescribing clinician based on the patient’s ovarian reserve, treatment protocol, and response to therapy. The prescriber determines the amount, frequency, and duration of administration to achieve the desired ovarian response while minimizing the risk of overstimulation.

Meriofert is intended for use before conception to facilitate ovulation and is not administered during an established pregnancy. Safety data for use while breastfeeding are limited; therefore, it is generally avoided in lactating women unless the benefits outweigh potential risks as assessed by the treating physician.

To request Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

Meriofert combines both FSH and LH activity in a single injectable formulation, which can simplify dosing compared with regimens that require separate FSH‑only and LH‑only preparations. Clinical efficacy is comparable to other recombinant gonadotropins when used according to established ART protocols, while the safety profile reflects the class‑wide risk of ovarian hyperstimulation.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If refrigeration is temporarily unavailable, the product may be kept at controlled room temperature for a limited period as indicated in the manufacturer’s label.

Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The healthcare professional prepares the dose according to the prescriber’s instructions, selects an appropriate injection site, and administers the medication using aseptic technique. Patients are monitored for response and any adverse reactions after each dose.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain, and respiratory compromise, as well as the possibility of multiple pregnancy and rare thromboembolic events. Prompt medical evaluation is required if patients experience significant abdominal distension, shortness of breath, or severe pain.

Meriofert should be avoided in individuals with known hypersensitivity to any component of the formulation, active ovarian cysts, uncontrolled thyroid disease, or severe uncontrolled systemic illness. It is also contraindicated in patients who are currently pregnant, as the medication is intended to induce ovulation prior to conception.